Cellulose for medical applications: Past, present, and future by Hoenich, N.
 
PEER-REVIEWED REVIEW ARTICLE                  ncsu.edu/bioresources 
 
 
Hoenich (2006). “Cellulose for medical applications,” BioResources 1(2), 270-280.   270 
 
CELLULOSE FOR MEDICAL APPLICATIONS:  PAST, PRESENT, 
AND FUTURE 
 
Nicholas Hoenich
 a 
 
Films and tubes manufactured from cellulose have historically been used 
in the treatment of renal failure, but their use for this purpose has 
declined in recent years in favour of films manufactured from synthetic 
material blends.  As the clinical application of cellulose for dialysis 
declines, new applications for its use are emerging, of which the most 
promising appears to be the use of microbial cellulose synthesized by 
Acetobacter xylinum as a novel wound healing system and as a scaffold 
for tissue regeneration. 
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HISTORICAL OVERVIEW 
 
  Cellulose is a naturally occurring material found in wood, cotton, hemp, and other 
plant-based materials, and consists of repeating anhydroglucose units joined by ß-(1,4) 
linkages, forming the basic repeating unit. It was first isolated from wood in 1885 by 
Charles F. Cross and Edward Bevan at the Jodrell Laboratory of the Royal Botanic 
Gardens, Kew, London.  The process for manufacturing cellulose film from viscose was 
discovered by three English chemists, Charles Frederick Cross, Edward John Bevan and 
Clayton Beadle in 1898. However it was not until 1913 that Dr Jacques Brandenberger 
developed thin transparent cellulose film into commercial production at the 'La 
Cellophane SA factory in Bezons, France.   
  Although the primary use of cellulose films has been for wrapping purposes, it 
has also found an application in the treatment of renal failure, as well as in a variety of 
more recent and evolving clinical applications such as for scaffolds in tissue engineering,  
temporary skin substitute, a haemostatic agent, post operative adhesion barrier, and as a 
culture material for hepatocytes. 
  In this paper, the use of cellulose in medical applications are reviewed and 
discussed.  
 
Cellulose for Use in the Treatment of Renal Failure  
  When the human kidney fails, either as a consequence of disease (chronic renal 
disease) or following traumatic injury, or the ingestion of poisons, the blood-borne 
metabolites of protein break down, water that would normally be handled by the kidney 
accumulates, and supportive therapy is required to sustain life. The most widely used 
treatment is haemodialysis, with over 1.1 million persons receiving such treatment  
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worldwide in 2002 (Lysaght 2002).  Haemodialysis refers to the dialysis of blood, during 
which the patient’s blood is passed through an artificial kidney or haemodialyser, 
containing a membrane. Blood flows on one side of the membrane, whilst the other side 
is bathed by an electrolyte or salt solution (dialysis fluid) continually produced by a 
proportionating system (the artificial kidney machine), which also monitors and controls 
treatment.  Molecules small enough to pass through the membrane, such as salts and low 
molecular protein breakdown products, tend to move in the direction of decreasing 
concentration. Larger substances, such as proteins and cells having dimensions greater 
than the pore diameter, are retained. Haemodialysis is generally performed three times 
weekly for patients with irreversible renal or kidney failure, whilst the treatment 
regimens for acute or reversible renal failure are governed by clinical requirements and 
may include intermittent or continuous treatment over a period of several days.   
  Although diffusion is the primary driving force within the dialyser for solute 
transport, other mechanisms, such as convection, a consequence of fluid flux across the 
membrane, and adsorption to the membrane, also make small contributions, and both 
have been developed to provide therapies for specific groups of patients (Rabindrahath et 
al. 2006).  
  The term dialysis was coined by Thomas Graham, Professor of Chemistry at 
Anderson's University in Glasgow. In 1861 his experiments demonstrated that crystal-
loids were able to diffuse through vegetable parchment coated with albumin (which acted 
as a semi-permeable membrane; Gottschalk et al. 1997).  Although Graham predicted that 
his findings might be applicable to medicine, he did not venture into this area. The first 
historical description of dialysis was published in 1913 when Abel, Rowntree and Turner 
“dialyzed” anesthetized animals by directing their blood outside the body and through 
tubes of semi-permeable membranes (Abel et al. 1990). These early membranes were 
made from a mixture of cotton and sulphuric and nitric acids, which were dissolved in 
alcohol.  The tubes, which were connected at either end to a glass manifold to receive and 
return the blood, were approximately 8 cm in length and were encased in a glass cylinder 
through which the dialysis fluid passed.  The tubes were in many respects similar to the 
hollow fibre designs in use today. Such membranes were difficult to produce and steril-
ise, and were subject to leakage and lacked consistency in pore size.  
  In 1925 Erwin O. Freund in Chicago discovered that he could make a sausage 
casing based on cellulose by the use of the viscose process. The cellulose was dissolved 
in alkali, producing a viscose solution, which when extruded into an acid bath converts 
the viscose into cellulose. This material became known as Visking tubing (Visking 
Corporation Chicago, Ill, USA). In the same year in  Europe, Kalle Ag (Wisebaden, 
Germany) began the production of Cellophane, and this material was used in the early 
treatments of acute or reversible kidney failure by Kolff in the Netherlands in the 1940s 
(Jacobze et al. 2005). For such treatments a long cellophane tube spirally wrapped around 
a cylinder and rotated in a stationary dialysis fluid bath was used.  The method was 
subsequently developed by Kolff and Berk, and became the first apparatus in widespread 
clinical use (Kolff et al. 1997). 
   The widespread application of haemodialysis for the treatment of renal failure 
became a possibility with the availability of robust methods to gain access to the patients’ 
circulation (Konner 2005). In parallel with this, several new designs of artificial kidney,  
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including the coil, parallel flow and the hollow fibre dialysers became available.  Early 
variants of such dialysers used membranes based on cellulose.  Worldwide, the largest 
producer of membranes suitable for use in the coil and parallel plate designs was J. P. 
Bemberg AG (Wuppertal, Germany ), who produced the membranes by the solubilisa-
tion of cellulose in an ammonia solution of cupric oxide (cuprammonium process).  The 
original variant of the hollow fibre dialyser utilized cellulose acetate as the membrane, 
which was produced by the Dow Chemical company and originally used for desalination 
applications (Gotch et al. 1969). European production of hollow fibres based on cellulose 
began some years later in 1974. 
  Clinical use of the coil dialysers has declined, but parallel plate devices such as 
those shown in Fig. 1 continue to be used. The majority of patients today receive their 
treatment using a hollow fibre dialyser (Fig. 2).  In such devices, which are available in a 
range of surface areas to meet differing clinical requirements, the hollow fibres have 
internal diameters within the range 180-220 µm and wall thicknesses between 6 and 15 
µm.  
 
Fig. 1.  Plate type dialyser utilizing sheet membranes supported on extruded polypropylene 
plates [Illustration courtesy of Gambro Ab, Lund, Sweden] 
 
 
CONTEMPORARY ISSUES 
 
  Concerns began in the 1970s regarding the narrow range of molecules that could 
be removed by cellulose membranes.  These concerns led to the development of 
membranes with an open-pored structure and new treatment techniques such as 
haemodiafiltration, a process in which whole blood is first diluted with physiologic 
electrolyte solution and then ultrafiltered across a membrane (Henderson et al. 1970).  
Since there were no cellulose-based membranes commercially available at that time that 
could meet the requirements of haemodiafiltration or haemofiltration, the procedure 
utilized membranes manufactured from synthetic polymer blends, such as the polysulfone 
membrane developed by the Amicon Corporation.  These membranes were highly  
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permeable, yielding high filtration rates at low transmembrane pressures.  Furthermore, 
they could be fabricated to provide good size selectivity, with a molecular cutoff of ca. 
50,000 Da. Subsequent modifications of the manufacturing process of cellulose-based 
membranes have meant that today cellulose membranes are available for use in these 
therapies.   
 
 
Fig. 2.  Contemporary hollow fibre dialysers are available in a variety of sizes to meet differing 
clinical treatment requirements [Illustration courtesy of Fresenius Medical care, Bad Homburg, 
Germany. 
 
  In contrast to cellulose-based membranes, membranes manufactured from syn-
thetic copolymers were associated with a reduced lecopaenia, or a transient loss of 
leucocytes from the circulation (Woffindin and Hoenich 1988). Subsequent research 
indicated that the leucopaenia was a consequence of pulmonary sequestration of the cells 
mediated by the contact of blood with the membrane surface (Craddock et al. 1977).  It is 
now well accepted that C3a, C5a, and the terminal complement complex (TCC) stimulate 
the expression of receptors on leucocytes, leading to aggregation and sequestration in the 
pulmonary microvasculature (Dhondt et al. 1998). The desire to minimize these 
responses resulted in the modification of the classical cellobiose unit of the cellulose 
strands in which the OH groups are either replaced or the blood contacting surface is 
coated by materials such as poly-ethylene glycol (PEG) to minimize blood exposure to 
the hydroxyl groups on the surface (see Fig. 3 and Table 1).     
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Fig. 3.  The chemical structure of cellulose membranes showing partial modification of the OH 
groups.  [DEAE = diethylaminoethyl; Ac = acetyl]   
 
    
 
Table 1.  Cellulose based Haemodialysis Membranes 
  
Cuprammonium rayon  Regenerated cellulose (unmodified)  
Cuprophan  Regenerated cellulose (unmodified)  
   
Hemophan  Cellulose etherified with dimethylaminoethyl DEAE 
Excerbane  Regenerated cellulose coated with Vitamin E 
PEG modified cellulose  Cuprammonium rayon coated with poly ethylene glycol 
(PEG)  
SMC  Synthetically modified cellulose in which there is benzyl 
group substitution of the hydroxyl groups  
Cellulose acetate   Regenerated cellulose esterified with acetate 
Cellulose tri-acetate   Regenerated cellulose esterified with 3.0 acetate  
Cellulose 2.5 acetate   Regenerated cellulose esterified with 2.5 acetate 
 
  Membranes were historically considered as inert phase separators; however, 
repeated blood contact takes place with the dialysis membrane, which typically has an 
area of 1–1.5 m
2. This contact results not only in the activation of the body’s humoral and 
cellular processes, but may also play a role in the outcomes associated with dialysis 
treatment. It is now recognised that patients receiving dialysis are subject to oxidative 
stress associated with the dialysis treatment, which contributes to the pathogenesis of  
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vascular injury and in the progression of atherosclerosis (Himmelfarb 2005). To 
minimize the activation of polymorphonuclear leukocytes on the surface of dialysis 
membranes, a vitamin E–coated cellulose membrane has recently been produced, which 
reduces oxidative stress induced by the treatment (Galli et al. 1998). 
  In the artificial kidney, the membrane acts as a semi-permeable barrier, separating 
the sterile blood side from the non-sterile dialysis fluid. Within the dialysis fluid, 
potential exists for bacterial contamination and the formation of biofilm in the dialysis 
machine or in the distribution systems delivering water to the dialysis machines (Tapia 
and Yee 2006). Bacteria, due to their size, cannot cross the membrane, but bacterial 
fragments or endotoxins are able to do so, and this has raised concerns that membranes 
with a large pore size may confer a risk to the patient of exposure to cytokine-inducing 
bacterial substances in the dialysate, contributing to the microinflammatory state of 
patients undergoing regular dialysis (Yao et al. 2004). 
  Membranes manufactured from cellulose are a homogenous gel, but membranes 
manufactured from polymer blends have a more complex structure. Several studies have 
reported higher transfer of cytokine-inducing bacterial substances through low-flux 
cellulosic compared to high-flux synthetic membranes (Weber et al. 2004a). This sur-
prising paradox is explained by adsorption of cytokine-inducing bacterial substances to 
synthetic membranes (Hayamaa et al. 2003). 
 
Other Medical Applications of Cellulose 
 
Wound care  
  If a wound is to heal effectively, it must be maintained in a wet condition. The 
best dressing is the patient’s own skin, which is permeable to vapour and protects the 
deeper layer tissue against mechanical injuries and infection. For many years biological 
dressings of pig skin or human cadaver skin have been used, but such products are 
expensive and may only be used for a short period.   
  Microbial cellulose synthesized by Acetobacter xylinum shows considerable 
potential as a novel wound healing system, resulting from its unique nanostructure.   
During the process of biosynthesis, various carbon compounds of the nutrition medium 
are utilized by the bacteria, then polymerized into single, linear β-1,4-glucan chains and 
finally secreted outside the cells through a linear row of pores located on their outer 
membrane. The subsequent assembly of the β-1,4-glucan chains outside of the cell is a 
precise, hierarchical process. Initially, they form sub-fibrils (consisting of 10–15 nascent 
β-1,4-glucan chains), then later micro-fibrils, and finally bundles of micro-fibrils 
consisting of a loosely wound ribbon. The thick, gelatinous membrane formed is 
characterized by a 3-D structure consisting of an ultrafine network of cellulose nanofibres 
(3–8nm) which are highly uniaxially oriented have a high cellulose crystallinity (60–
80%) and mechanical strength. 
  The first efforts to commercialize microbial cellulose on a large scale were 
initiated by Johnson & Johnson in the early 1980s. The patents arising from this work 
were subsequently licensed to Xylos, a company responsible for the manufacture of The 
XCell® family of wound-care products.   
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  A number of other commercial and academic institutions are developing this 
material.  A Brazilian company, BioFill Produtos Bioetecnologicos (Curitiba, PR Brazil), 
produces a range of products based on this material, including Biofill
® and Bioprocess
® 
(used in the therapy of burns, ulcers as temporary artificial skin), and Gengiflex
® (applied 
in treatment of periodontal diseases; Fontana et al. 1990).  
  Several Japanese companies and national governmental organizations have 
collaborated to set up interdisciplinary research programs, whilst the Technical Univer-
sity of Lodz in Poland has undertaken basic research studies on cellulose biosynthesis 
(Czaja et al. 2006).   
A number of questions concerning this material remain unresolved. First, there is 
no clear indication as to its mechanisms of action, which is most likely to be a result of its 
unique nanostructure, creating optimal moist conditions for wound healing and skin 
regeneration. Production factors influencing its mode of action remain undefined, and the 
availability of large-scale, efficient fermentation for production is lacking.  
 
Encapsulation  
  Activated charcoal is effective for the direct removal of various circulating toxic 
materials and waste metabolites from the blood (haemoperfusion).  It may be used in the 
treatment of poisonings, as well as a bridge to liver transplantation, and occasionally in 
acute liver failure until the liver regenerates (in conjunction with other treatment modali-
ties).  The use of uncoated charcoal, however, is associated with adverse effects, such as 
hypotension and the appearance of platelet aggregates in the circulation, as well as parti-
culate release. Coating of the material results in an improved biocompatibility, and a 
variety of coatings, including cellulose nitrate have been used (Chang 1984).  
  Materials other than charcoal, as well as cells may be encapsulated for a variety of 
clinical applications.  Cellulose acetate butyrate microcapsules, as well as cellulose-based 
microspheres, have been used for the delivery of drugs (Lin and Wu 1999; Weber et al. 
2004b; Fundueanu et al. 2005; Zhou et al. 2005).  More recently, this approach has been 
extended to bovine spermatozoa (Weber et al. 2006).  
  Acute renal failure frequently occurs following sepsis.  The removal of endotox-
ins by extracorporeal adsorption processes is a promising approach to the treatment of 
Gram-negative sepsis and endotoxin shock. Microspheres manufactured by coating a 
cellulose matrix with polyethyleneimine have demonstrated high adsorptive capacity for 
endotoxins (Weber et al. 1995; Fang et al. 2004; Taniguchi et al. 2006).  
 
Cellulose as an implant material  
  Sutures are the largest group of devices implanted into humans. Silk is a 
traditional fiber used as sutures in medical applications. Although biodegradable, its 
major disadvantage is its lower tensile strength and reaction with tissues. The problem of 
strength retention in the case of bio-absorbable commercial sutures is being tackled by 
different surface modification techniques. Polypropylene and polyester filament coated 
with Teflon, for example, are employed for vascular surgery. Sutures by the modification 
of cellulose filaments also have been produced.  Carbon fiber based sutures also have 
been produced by the modification of cellulose filaments (Narat et al. 1950).    
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  Bacterial cellulose derived from Acetobacter xylinum has an ultrafine network 
architecture, high hydrophilicity, and mouldability during formation.  In addition to the 
applications discussed, it is also suitable for use in micronerve surgery and as an artificial 
blood vessel suitable for microsurgery.  Such products in the form of BActerisal 
Synthesized Cellulose (BASYC®) have been described in the literature (Klemm et al. 
2001). 
  Haemorrhage continues to be a serious complication of surgical procedures. 
Surgicel® (oxidized regenerated cellulose) is used widely to control haemorrhage, as this 
material, when saturated with blood, swells rapidly (Sharma et al. 2003).      
  One of the goals of tissue engineering is to manufacture scaffolds, suitable for 
transplantation, which are infiltrated with cells. Both viscose cellulose sponges and non-
woven cellulose have been used experimentally to fabricate cartilage transplants 
(Pulkkinen et al. 2006; Muller et al. 2006).  Cellulose derived from Acetobacter xylinum, 
as discussed above in the context of wound healing, has also been explored as a potential  
scaffold material, due to its unusual material properties and degradability (Svensson et al. 
2005).  
 
 
THE FUTURE  
 
  The most widely used application of cellulose in medicine has been as a mem-
brane in the treatment of renal failure.  Worldwide trends in the use of membranes for the 
treatment of chronic renal failure indicate a move away from cellulose-based membranes 
in favour of synthetic membranes (Grassmann et al. 2005).   
  There are many reasons for this trend. But an important question is whether 
patients treated with cellulose membranes are at a disadvantage, compared to patients 
receiving treatment using synthetic membranes, in terms of outcomes and wellbeing. 
Historic studies suggested that this may have been the case, but a recent Cochrane review 
found no evidence of benefit when synthetic membranes were compared with cellulose 
membranes or modified cellulose membranes in terms of reduced mortality or the 
reduction in dialysis-related adverse symptoms (Macleod et al. 2005). Despite this 
review, the European Best practice guidelines suggest that dialyser membranes with the 
lowest degree of complement and leukocyte activation should be applied. Dialyser 
membranes that induce strong complement and leukocyte activation, inflammatory 
reactions, and/or a blunting of the response of leukocytes to stimuli should be avoided 
(Anon. 2002).   This set of practices certainly precludes the continuing use of unmodified 
cellulose membranes.  Discontinuation of the use of modified cellulose membranes in 
favour of synthetic membranes is, however, less compelling, since such membranes 
overlap in terms of their biocompatibility with those manufactured from synthetic 
materials (Hoenich et al. 1995).  Furthermore, there may be other factors, such as cost, 
favouring the continuing use of such membranes in emerging economies.   
  As the clinical application of cellulose in the form of membranes for dialysis 
declines, new applications are emerging. Of these, the most promising appears to be the 
use of microbial cellulose synthesized by Acetobacter xylinum as a novel wound healing 
system.   
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